Rockville, March 14, 2023 (GLOBE NEWSWIRE) -- The Omics Based Clinical Trials Market revenues were estimated at US$ 26.2 Bn in 2021 and is anticipated to grow at a CAGR of 8.1% from 2022-2032, according to a recently published Fact.MR report. By the end of 2032, the market is expected to reach US$ 61.7 Bn. Interventional Studies is projected to remain lucrative in the market throughout the analysis period.
The COVID-19 outbreak lead to significant investment in the pharmaceutical industry by key market participants, which also led a positive impact on omics-based clinical trials, where an increase in the frequency of chronic illnesses were the primary factors. Researchers are looking at numerous biological targets that could serve as indicators of clinical risk as well as therapeutic targets in light of the increased global prevalence and burden of chronic diseases such as cancer.
Download Free Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=7170
Though the pandemic has caused substantial supply chain roadblocks in the pharmaceutical industry, on the other hand, it had a plethora of omics based findings. Using an integrative investigation of genomic, proteomic, transcriptomic, lipidomic, and metabolomic profiles, a trans-omics landscape for COVID-19 was discoveredThe market for omics-based clinical trials has observed a substantial number of consolidations in recent years in the pharmaceutical industry.
Report Attributes | Details |
| Forecast Period | 2022 - 2033 |
| Value Projection (2032) | US$ 61.7 Billion |
| Growth Rate (2022-2032) | 8.1% CAGR |
| No. of Pages | 170 pages |
| No. of Tables | 72 Tables |
| No. of Figures | 148 Figures |
Key Takeaways from the Market Study
- Global Omics Based Clinical Trials Market is expected to reach a market size of US$ 28.3 Bn by 2022.
- The phase II segment, which accounted for 37.2% of total revenue in 2021, dominated the market for omics-based clinical trials.
- Interventional Studies is expected to be the highest revenue generating segment between 2022 and 2032, with an expected growth of 4.9X.
- North America is projected to experience a CAGR of 8.1% across the 2022-2032 forecast period.
Omics has shown to be the most advanced method for molecular research. It includes all biological sciences subjects with the suffix -omics at the end. The epidemic of the coronavirus has accelerated the application of novel approaches, models, and technologies in clinical trials, boosting market growth, comments a Fact.MR analyst.
How is Rising Chronic Disease Boosting Growth of Omics Based Clinical Trials Market?
Because of the Coronavirus epidemic, interest in the drug business was expanded fundamentally by noticeable entertainers to build their efficiency. This likewise helped the interest for omics-based clinical trials. With the rising worldwide pervasiveness and weight of ongoing illnesses, for example, disease, scientists are taking a gander at a few natural focuses on that could act as biomarkers of clinical gamble as well as helpful targets.
Omics based clinical, preliminaries has demonstrated to be the most developed sub-atomic examination technique. It incorporates all natural sciences handles that close with the addition - omics. Proteomics, genomics, transcriptomics, and metabolomics are a couple of the omics fields. The Covid episode has rushed the utilization of new procedures, models, and advancements in clinical preliminaries, which has helped market development.
Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=7170
Key Companies Profiled in Omics Based Clinical Trials Market report
- Parexel International Corporation
- Pharmaceutical Product Development (PPD)
- Charles River Laboratory
- ICON plc
- SGS SA
- Eli Lilly and Company
- Pfizer Inc.
- Covance Inc.
- Rebus Bio
Competitive Landscape
The market for omics-based clinical trials is extremely competitive due to the presence of a significant number of developed as well as medium to small-sized organizations. The increased frequency of chronic diseases including cancer and heart disorders, as well as the growing demand for omics-based clinical trials in emerging countries, are propelling the market forward. Several strategies are being employed by companies to remain competitive.
- In December 2021, Rebus Biosystems Inc., a US-based life science technology company, announced that it has acquired the assay assets and intellectual property of EEL Transcriptomics AB, a privately held company specialized on high-plex spatial transcriptomics with single-cell resolution.
- In November 2021, ICON plc announced that its Accellacare Site Network had expanded its reach and capabilities as a consequence of new partnerships with six research sites in four countries.
- In February 2021, Parexel and Neo Genomics formed a precision medicine strategic alliance, with an objective of improving study designs and accelerating patient matching in oncology clinical trials.
Quick Buy & Expand Your Horizons (Get 20% Discount): https://www.factmr.com/checkout/7170
Market Segments Covered in Omics Based Clinical Trials Market Analysis
- By Phase Type :
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- By Study Design Type :
- Interventional Studies
- Observational Studies
- Expanded Access Studies
- By Indication :
- Oncology
- Cardiology
- Respiratory Diseases
- Skin Diseases
- CNS Diseases
- Immunology
- Genetic Diseases
- Other Indications
More Insights Available
Fact.MR, in its new offering, presents an unbiased analysis of the Omics Based Clinical Trials Market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032.
The study reveals extensive growth in Omics Based Clinical Trials Market by by Phase Type (Phase 1, Phase 2, Phase 3, Phase 4), by Study Design Type (Interventional Studies, Observational Studies, Expanded Access Studies), by Indication (Oncology, Cardiology, Respiratory Diseases, Skin Diseases, CNS Diseases, Immunology, Genetic Diseases, Other Indications), across five regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).
Explore More Related Studies Published by Fact.MR Research:
Clinical Grade Disinfectant Market: Clinical Grade Disinfectant Market By Formulation (Quaternary Ammonium Compounds, Chlorine Compounds, Alcohols & Aldehydes, Phenolic Compounds), By End-User, By Sales Channel, By Region - Global Market Insights 2020 to 2030
Clinical Trial Imaging Market: Clinical Trial Imaging Market Analysis By Service (Project & Data Management, Operational Imaging Services, Reading & Analytical Services, Others), By Application (Non-alcoholic Steatohepatitis, Oncology, Neurology, Endocrinology, Cardiology, Others), By End User & Region - Global Market Insights 2023–2033
Clinical Trial Management Systems Market: Clinical Trial Management Systems Market Analysis, By Mode of Deployment (Cloud-based, Web-based, On-premise), By Component (Hardware, Software, Services), By Product Type (Enterprise-based, Site-based), By End User, By Region - Global Insights 2022-2032
About Fact.MR
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Connect to Author: Mr. Shambhu Nath Jha
Email: shambhu@factmr.com
Sales Team: sales@factmr.com
Follow Us: LinkedIn | Twitter | YouTube
